ArticleFrontiers in endocrinology2022
PQQ Dietary Supplementation Prevents Alkylating Agent-Induced Ovarian Dysfunction in Mice.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Dietary pyrroloquinoline quinone supplementation improves productive performance, immunity, and intestinal health in late-phase Jingfen No. 6 laying hens.Poultry science · 2026Article
- An integrated anti-aging framework targeting NADRedox biology · 2026Review
- A role for the antioxidants coenzyme Q10 and pyrroloquinoline quinone in mitigating obesity-associated reproductive dysfunction†.Biology of reproduction · 2026Review
- Proteomic profiling reveals the molecular signatures of chemotherapy-induced human ovarian damage.Human reproduction (Oxford, England) · 2025Article
- Current study on Pyrroloquinoline quinone (PQQ) therapeutic role in neurodegenerative diseases.Molecular biology reports · 2025Review
- Pyrroloquinoline Quinone Improved Boar Sperm Quality via Maintaining Mitochondrial Function During Cryopreservation.Antioxidants (Basel, Switzerland) · 2025Article
- Loss of p21 does not protect against premature ovarian insufficiency caused by alkylating agents.Frontiers in endocrinology · 2025Article
- Pre-conditioning with PQQ during pregnancy alleviates LPS-induced placental damage and improves the fetal survival and growth in mice.Frontiers in endocrinology · 2025Article
- CompoundAnimal nutrition (Zhongguo xu mu shou yi xue hui) · 2024Article
- New insights on mitochondrial heteroplasmy observed in ovarian diseases.Journal of advanced research · 2024Review
- Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage.Human reproduction update · 2024Review
- Nrf2 activation by pyrroloquinoline quinone inhibits natural aging-related intervertebral disk degeneration in mice.Aging cell · 2024Article
- Pyrroloquinoline quinone promotes human mesenchymal stem cell-derived mitochondria to improve premature ovarian insufficiency in mice through the SIRT1/ATM/p53 pathway.Stem cell research & therapy · 2024Article
- Oxidative stress resistance prompts pyrroloquinoline quinone biosynthesis in Hyphomicrobium denitrificans H4-45.Applied microbiology and biotechnology · 2024Article
- Pyrroloquinoline Quinone Improves Ram Sperm Quality through Its Antioxidative Ability during Storage at 4 °C.Antioxidants (Basel, Switzerland) · 2024Article
- Chemoprotective effect of baicalin against cyclophosphamide induced ovarian toxicity in mice via inhibition of TGF-β.Heliyon · 2023Article
- The EZH2-H3K27me3 axis modulates aberrant transcription and apoptosis in cyclophosphamide-induced ovarian granulosa cell injury.Cell death discovery · 2023Article
- Pyrroloquinoline quinone alleviates natural aging-related osteoporosis via a novel MCM3-Keap1-Nrf2 axis-mediated stress response and Fbn1 upregulation.Aging cell · 2023Article
- Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents.BMC pregnancy and childbirth · 2023Article
- An Efficient UPLC-MS/MS Method for the Determination of Pyrroloquinoline Quinone in Rat Plasma and Its Application to a Toxicokinetic Study.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alkylating agents (AAs) that are commonly used for cancer therapy cause great damage to the ovary. Pyrroloquinoline-quinine (PQQ), which was initially identified as a redox cofactor for bacterial dehydrogenases, has been demonstrated to benefit the fertility of females. The aim of this study was to investigate whether PQQ dietary supplementation plays a protective role against alkylating agent-induced ovarian dysfunction. A single dose of busulphan (20 mg/kg) and cyclophosphamide (CTX, 120 mg/kg) were used to establish a mouse model of ovarian dysfunction. Feed containing PQQNa
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.